T2D2017

Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes

Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes

By

A study of the once-weekly investigational dipeptidyl peptidase-4 omarigliptin reported a clinically meaningful reduction in glycated hemoglobin that was maintained throughout the study.

T2D and Magnesium Intake: Risk of Incident Diabetes Examined

T2D and Magnesium Intake: Risk of Incident Diabetes Examined

By

Higher magnesium intake was linked to a 15% lower risk for type 2 diabetes.

Reducing HbA1c in T1D and T2D With Flash Glucose Monitoring

Reducing HbA1c in T1D and T2D With Flash Glucose Monitoring

By

Overall reduction in HbA1c was higher in people with T2D vs those with T1D.

No Fingerstick Necessary: FDA Approves Novel CGM System for Diabetes

No Fingerstick Necessary: FDA Approves Novel CGM System for Diabetes

By

New monitoring system involves the placement of a small sensor wire beneath the skin surface to continuously monitor glucose levels.

How Does Lifestyle Intervention Benefit Glycemic Control in T2D?

How Does Lifestyle Intervention Benefit Glycemic Control in T2D?

By

Researchers examined the efficacy of lifestyle intervention on glycemic control in type 2 diabetes.

GSK Announces Discontinuation of Injectable Therapy for T2D

GSK Announces Discontinuation of Injectable Therapy for T2D

By

GlaxoSmithKline expects Tanzeum supplies to be depleted by July 2018.

FDA: Liraglutide Approved for MACE in T2D With Established CVD

FDA: Liraglutide Approved for MACE in T2D With Established CVD

By

Approval for the new indication follows a review of the results of the LEADER trial.

SGLT2 Inhibitors May Reduce Blood Pressure in Type 2 Diabetes

SGLT2 Inhibitors May Reduce Blood Pressure in Type 2 Diabetes

By

Sodium-glucose cotransporter 2 inhibitors reduced both systolic and diastolic blood pressure in patients with type 2 diabetes.

Acceptable Variability With Novel Sensor for Glucose Monitoring in T2D

Acceptable Variability With Novel Sensor for Glucose Monitoring in T2D

By

One hundred fifteen patients used the FreeStyle Libre Pro sensor to monitor interstitial fluid glucose for 14 days.

Ertugliflozin Plus Metformin Improves Glycemic Control in Type 2 Diabetes

Ertugliflozin Plus Metformin Improves Glycemic Control in Type 2 Diabetes

By

A randomized double-blind trial examined the safety and efficacy of ertugliflozin plus metformin for inadequately controlled type 2 diabetes.

Canagliflozin Reduces Cardiovascular Stress in Older Patients With T2D

Canagliflozin Reduces Cardiovascular Stress in Older Patients With T2D

By

Canagliflozin reduced levels of cardiovascular stress biomarkers N-terminal pro-B type natriuretic peptide and high sensitivity troponin I.

Reduced Cardiovascular Events in T2D Treated With Dapagliflozin

Reduced Cardiovascular Events in T2D Treated With Dapagliflozin

By

Patients with type 2 diabetes had lower rates of heart failure hospitalization, MACE, and all-cause mortality when treated with dapagliflozin.

Insulin Sensitivity Not Affected by Vitamin D Supplementation in T2D

Insulin Sensitivity Not Affected by Vitamin D Supplementation in T2D

By

No between-group differences for factors such as glycemic control, endogenous glucose production, and insulin sensitivity were found.

FDA Adds Boxed Warning to Canagliflozin Due to Increased Leg, Foot Amputation Risk

FDA Adds Boxed Warning to Canagliflozin Due to Increased Leg, Foot Amputation Risk

By

Results of 2 large clinical trials confirmed previous safety concerns surrounding canagliflozin therapy for type 2 diabetes.

Liraglutide Plus Metformin Leads to Remission in New-Onset T2D

Liraglutide Plus Metformin Leads to Remission in New-Onset T2D

By

The combined treatment regimen of metformin and liraglutide led to complete remission in 74% of patients with new onset type 2 diabetes.

Early Insulin Therapy Improves Type 2 Diabetes Care

Early Insulin Therapy Improves Type 2 Diabetes Care

By

Early initiation of insulin therapy in patients with type 2 diabetes improved HbA1c, fasting blood sugar, postprandial blood sugar, and BMI.

Hypovitaminosis D Associated With High 24-Hour Ambulatory BP in T2D

Hypovitaminosis D Associated With High 24-Hour Ambulatory BP in T2D

By

Researchers examined 24-hour and ambulatory blood pressure to determine the relationship between hypertension and low levels of vitamin D.

Differential Adverse Renal Effects With Dapagliflozin, Empagliflozin in T2D

Differential Adverse Renal Effects With Dapagliflozin, Empagliflozin in T2D

By

A comprehensive systematic review analyzes whether specific sodium-glucose cotransporter 2 inhibitors were more likely to be associated with adverse renal events in patients with type 2 diabetes.

MACE Risk With Insulin Dosage in Type 2 Diabetes

MACE Risk With Insulin Dosage in Type 2 Diabetes

By

A cohort study of primary care records in the United Kingdom did not find an increased risk of major cardiovascular events in patients with type 2 diabetes treated with insulin.

Low Vitamin B12 Levels Associated With Long-Term Metformin Use

Low Vitamin B12 Levels Associated With Long-Term Metformin Use

By

Researchers found that those at risk for low vitamin B12 levels are often not properly monitored.

Sign Up for Free e-Newsletters

CME Focus